Literature DB >> 23598988

Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.

James K McCloskey1, Catherine M Broome, Bruce D Cheson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23598988

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  7 in total

Review 1.  Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

Authors:  Othman Al-Sawaf; Paula Cramer; Valentin Goede; Michael Hallek; Natali Pflug
Journal:  Ther Adv Hematol       Date:  2017-03-30

Review 2.  Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.

Authors:  Mona Darwish; Mary Bond; Edward Hellriegel; Philmore Robertson; James P Chovan
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-01       Impact factor: 3.333

Review 3.  Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.

Authors:  Lidia Gil; Maciej Kazmierczak; Renata Kroll-Balcerzak; Mieczyslaw Komarnicki
Journal:  Med Oncol       Date:  2014-04-22       Impact factor: 3.064

4.  Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.

Authors:  Fevzi Fırat Yalnız; Nihan Akkoç; Ayşe Salihoğlu; M Cem Ar; Şeniz Öngören; A Emre Eşkazan; Teoman Soysal; Yıldız Aydın
Journal:  Turk J Haematol       Date:  2017-03-08       Impact factor: 1.831

5.  Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells.

Authors:  Masaya Inoue; Yoshio Honma; Takeshi Urano; Junji Suzumiya
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

6.  Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.

Authors:  Nobuya Hiraoka; Jiro Kikuchi; Takahiro Yamauchi; Daisuke Koyama; Taeko Wada; Mitsuyo Uesawa; Miyuki Akutsu; Shigehisa Mori; Yuichi Nakamura; Takanori Ueda; Yasuhiko Kano; Yusuke Furukawa
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 7.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.